Form 4: ORIC CEO Sells 125,000 Shares Under 10b5-1 Plan

Oric Pharmaceuticals President and CEO Jacob Chacko sold 125,000 shares of common stock for approximately $1.35 million under a pre-arranged trading plan.

Summary

• Jacob Chacko, President and CEO of Oric Pharmaceuticals, Inc. (ORIC), disposed of 125,000 shares of common stock.
• The transaction occurred on September 22, 2025.
• The shares were sold at a weighted average price of $10.7995 per share, totaling approximately $1,349,937.50.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Chacko on June 21, 2025.
• Following the reported transaction, Mr. Chacko directly beneficially owns 656,419 shares of common stock.
• This beneficial ownership includes 2,771 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan.
• Mr. Chacko also holds 178,667 restricted stock units (RSUs) and stock options to purchase 3,378,000 shares, which are not included in the reported common stock ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it represents insider selling, the transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned financial event rather than a reaction to new, undisclosed negative information. This mitigates potential negative interpretations.

Negatives

• Insider selling by a key executive, even if pre-planned, can sometimes be perceived negatively by the market as it reduces direct ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is an individual insider transaction report and does not directly relate to broader industry trends or competitor activities, beyond reflecting a personal financial decision by a key executive in the biotechnology sector.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though the 10b5-1 plan context often lessens this impact. It indicates a reduction in direct ownership by a key executive.

Key Dates

Recommendation

The sale by President and CEO Jacob Chacko was conducted under a Rule 10b5-1 trading plan, established well in advance of the transaction date. This indicates a pre-planned diversification or liquidity event rather than a reactive sale based on immediate company performance or outlook. While insider selling can sometimes be a negative signal, the 10b5-1 plan mitigates concerns about its implications for the company's near-term prospects. Investors should monitor future filings and company performance, but this specific transaction does not warrant a change in investment thesis.

Keywords

ORIC, Oric Pharmaceuticals, Jacob Chacko, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, CEO, Biotechnology